Thus, in the context of TB treatment, current second-line regimens include the use of fluoroquinolones (FQs) (i.e., moxifloxacin, the most active FQ against TB, Figure 1A),2 a family of synthetic inhibitors specific to type II bacterial topoisomerases (DNA gyrase and Topo IV). Here, TOP2A is linked to tuberculosis.